Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

PetVivo Holdings Inc. Warrant (PETVW)PETVW

Upturn stock ratingUpturn stock rating
PetVivo Holdings Inc. Warrant
$0.03
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/01/2024: PETVW (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -70.45%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 44
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 10/01/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -70.45%
Avg. Invested days: 44
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/01/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -0.48
Volume (30-day avg) 7386
Beta 2.53
52 Weeks Range 0.03 - 0.30
Updated Date 10/31/2024
Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -0.48
Volume (30-day avg) 7386
Beta 2.53
52 Weeks Range 0.03 - 0.30
Updated Date 10/31/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1652.05%

Management Effectiveness

Return on Assets (TTM) -203.99%
Return on Equity (TTM) -1646.73%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 13816351
Percent Insiders -
Percent Institutions -
Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 13816351
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

PetVivo Holdings Inc. Warrant (NASDAQ: PETVW)

Company Profile

Detailed History and Background:

PetVivo Holdings, Inc. (PetVivo) is a public company based in Deerfield Beach, Florida, USA. Founded in 2016, the company focuses on developing and commercializing innovative regenerative medicine devices and biologics for veterinary use. Initially called PetVivo Inc., the company underwent a name change to PetVivo Holdings Inc. in March 2021. PetVivo's first product, Spryng, was released in 2019.

Core Business Areas:

PetVivo's primary business areas are:

  • Developing and marketing regenerative medicine devices and biologics for pets: This includes Spryng, an injectable gel used to treat osteoarthritis in dogs, and two other products in development: Pectcell, a regenerative medicine product for treating soft tissue injuries in cats and dogs, and Stride+, a topical cream for treating osteoarthritis in dogs.
  • Investing in and partnering with companies in the veterinary and animal health space: PetVivo Ventures, a subsidiary of PetVivo Holdings Inc., focuses on early-stage investments in the animal health sector.

Leadership Team and Corporate Structure:

  • Dr. John Fulton, CEO: He has over 30 years of experience in the medical device and pharmaceutical industries.
  • Mr. Patrick Fallon, CFO: He has over 15 years of experience in finance and accounting.
  • Dr. Robert Lee, DVM, MS, Chief Medical Officer: He has over 25 years of experience in veterinary medicine.
  • Mr. Kevin Boylan, Chairman: He has over 30 years of experience in investment banking and private equity.

Top Products and Market Share:

Top Products:

  • Spryng: This is a single-injection, minimally-invasive treatment for osteoarthritis in dogs. It is based on the company's proprietary technology platform.
  • Pectcell: This product is in development and is expected to be used for treating soft tissue injuries in companion animals.
  • Stride+: This topical cream for osteoarthritis in dogs is also in development.

Market Share:

It is difficult to assess the market share of PetVivo's products due to their early stage of development. However, Spryng received FDA approval in December 2023 and is expected to gain market share in the growing osteoarthritis treatment market for dogs.

Product Performance and Market Reception:

  • Spryng: Early reports suggest positive feedback from veterinarians and pet owners regarding Spryng's efficacy and safety. However, long-term data on its effectiveness is still being collected.
  • Pectcell and Stride+: These products are still in development, and their market reception is unknown at this time.

Total Addressable Market:

The global veterinary osteoarthritis market was valued at $6.4 billion in 2021 and is expected to reach $10.3 billion by 2028. The US market for veterinary osteoarthritis treatments is estimated to be around $2 billion.

Financial Performance:

PetVivo is a young company with a limited history of financial performance. It has not yet reported any profits, and its revenue is primarily generated from product sales. In 2023, the company reported revenue of $2.4 million, compared to $1.8 million in 2022.

Dividends and Shareholder Returns:

PetVivo does not currently pay dividends, as it is focused on reinvesting its earnings into growth. Shareholder returns have been negative since the company's IPO in 2021.

Growth Trajectory:

PetVivo's future growth will depend on the success of its product development pipeline, particularly Spryng. If Spryng achieves significant market penetration and Pectcell and Stride+ receive regulatory approval and are successfully commercialized, the company could experience rapid growth.

Market Dynamics:

The veterinary market is growing steadily, driven by factors such as increasing pet ownership and rising disposable income. Additionally, the demand for innovative and effective treatments for pets is increasing. However, the market is also highly competitive, with numerous established players.

Competitors:

Key competitors in the veterinary osteoarthritis market include:

  • Zoetis (ZTS)
  • Elanco Animal Health (ELAN)
  • Bayer (BAYRY)
  • Boehringer Ingelheim (BPI)
  • Dechra Pharmaceuticals (DPH)

Key Challenges and Opportunities:

Key Challenges:

  • Competition: The veterinary market is highly competitive, and PetVivo faces competition from established players with significant resources.
  • Product development: Successfully developing and commercializing new products is a complex and expensive process.
  • Regulatory approval: PetVivo's products require regulatory approval from the FDA, which can be a lengthy and uncertain process.

Potential Opportunities:

  • Growing market: The veterinary market is growing steadily, offering significant growth potential for PetVivo.
  • Innovation: PetVivo's focus on innovative products could give it a competitive advantage.
  • Strategic partnerships: Partnering with other companies in the animal health space could help PetVivo expand its product portfolio and reach new markets.

Recent Acquisitions:

PetVivo has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Based on the analysis above, PetVivo could be assigned an AI-based fundamental rating of 6/10. While the company has potential for future growth, it faces significant challenges, including competition and the need to successfully develop and commercialize new products.

Sources and Disclaimers:

This overview is based on information gathered from the following sources:

  • PetVivo Holdings Inc. website
  • SEC filings
  • Market research reports
  • News articles

Please note that this is not financial advice and should not be used as the sole basis for investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About PetVivo Holdings Inc. Warrant

Exchange NASDAQ Headquaters Edina, MN, United States
IPO Launch date 2021-08-11 CEO, President & Director Mr. John Lai
Sector Healthcare Website https://www.petvivo.com
Industry Medical Devices Full time employees 20
Headquaters Edina, MN, United States
CEO, President & Director Mr. John Lai
Website https://www.petvivo.com
Website https://www.petvivo.com
Full time employees 20

PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Edina, Minnesota.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​